1
|
Aghaei Delche N, Kheiri R, Ghorbani Nejad B, Sheikhi M, Razavi MS, Rahimzadegan M, Salmasi Z. Recent progress in the intranasal PLGA-based drug delivery for neurodegenerative diseases treatment. Iran J Basic Med Sci 2023; 26:1107-1119. [PMID: 37736505 PMCID: PMC10510483 DOI: 10.22038/ijbms.2023.70192.15264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Figures] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Accepted: 04/26/2023] [Indexed: 09/23/2023]
Abstract
One of the most challenging problems of the current treatments of neurodegenerative diseases is related to the permeation and access of most therapeutic agents to the central nervous system (CNS), prevented by the blood-brain barrier (BBB). Recently, intranasal (IN) delivery has opened new prospects because it directly delivers drugs for neurological diseases into the brain via the olfactory route. Recently, PLGA-based nanocarriers have attracted a lot of interest for IN delivery of drugs. This review gathered clear and concise statements of the recent progress of the various developed PLGA-based nanocarriers for IN drug delivery in brain diseases including Alzheimer's, Parkinson's, brain tumors, ischemia, epilepsy, depression, and schizophrenia. Subsequently, future perspectives and challenges of PLGA-based IN administration are discussed briefly.
Collapse
Affiliation(s)
| | - Reyhaneh Kheiri
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Behnam Ghorbani Nejad
- Department of Toxicology and Pharmacology, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran
| | - Mojgan Sheikhi
- Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Malihe Sadat Razavi
- Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
- Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Milad Rahimzadegan
- Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Zahra Salmasi
- Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|
2
|
Kheiri R, Koohi MK, Sadeghi-Hashjin G, Nouri H, Khezli N, Hassan MA, Hoomani F, Shams G, Rasouli A, Motaghinejad M. Comparison of the Effects of Iron Oxide, as a New Form of Iron Supplement, and Ferrous Sulfate on the Blood Levels of Iron and Total Iron-Binding Globulin in the Rabbit. Iran J Med Sci 2017; 42:79-84. [PMID: 28293054 PMCID: PMC5337769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Iron oxide is an important biological agent that has a key role in medical processes; however, the mechanism whereby it provides iron for human and animal cells and its biological uses remains unclear. We aimed to evaluate the effects of oral iron oxide on serum iron status and compare the results with those of iron sulfate as a reference salt. Fifteen adult rabbits were divided into 3 groups of 5 each: control group, iron sulfate group, and iron oxide group. The groups received doses of 3.3, 10, and 33 mg/kg in 3 experiments. Venous blood samples were obtained just before the oral administration of iron sulfate and iron oxide (3.3 mg/kg). More blood samples were taken 3 times at the time points of 1, 6, and 12 hours after the administration of the solutions. Serum was separated for the measurement of iron (Fe) and total iron-binding globulin (TIBG) with routine methods. One week later, the same experiment was repeated with 10 mg/kg of iron sulfate and iron oxide; and 1 week later after the second experiment, again the same experiment was repeated with 33 mg/kg of iron sulfate and iron oxide. The results showed that 33 mg/kg of iron sulfate 1 hour after treatment caused a significant difference in the Fe and TIBG levels between all the groups (P=0.014 for Fe and P=0.027 for TIBG). Our data showed that the absorption of iron oxide was similar to that of ferrous sulfate and in high doses was as useful as iron supplement.
Collapse
Affiliation(s)
- Reyhaneh Kheiri
- Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Mohammad Kazem Koohi
- Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
| | | | - Hadiseh Nouri
- Pharmacology Section, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
| | - Noushin Khezli
- Pharmacology Section, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
| | | | - Fatemeh Hoomani
- Department of Nursing, School of Nursing and Midwifery, Islamic Azad University, Arak Branch, Arak, Iran
| | - Gholamreza Shams
- Pharmacology Section, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
| | - Ali Rasouli
- Pharmacology Section, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
| | - Majid Motaghinejad
- Department of Pharmacology, School of Medicine and Razi Institute for Drug Research, Iran University of Medical Sciences, Tehran, Iran,Correspondence: Majid Motaghinejad, PhD; Department of Pharmacology, School of Medicine, and Razi Institute for Drug Research, Iran University of Medical Sciences, P.O. Box: 14155-6183, Tehran, Iran Tel: +98 21 88622696 Fax: +98 21 88622696
| |
Collapse
|